The Crisis We Are Not Talking About: One-in-Three Annual HIV Seroconversions Among Sexual and Gender Minorities Were Persistent Methamphetamine Users : JAIDS Journal of Acquired Immune Deficiency Syndromes

Secondary Logo

Journal Logo


The Crisis We Are Not Talking About: One-in-Three Annual HIV Seroconversions Among Sexual and Gender Minorities Were Persistent Methamphetamine Users

Grov, Christian PhD, MPHa,b; Westmoreland, Drew PhDa; Morrison, Corey BSa; Carrico, Adam W. PhDc; Nash, Denis PhDa,b

Author Information
JAIDS Journal of Acquired Immune Deficiency Syndromes 85(3):p 272-279, November 01, 2020. | DOI: 10.1097/QAI.0000000000002461
  • Free



Methamphetamine, known colloquially as meth, crystal, or ice, is an addictive and potent stimulant drug that may be smoked, snorted, injected, or orally ingested.1,2 For a period of time, many components necessary to manufacture methamphetamine could be purchased over-the-counter, and the drug itself could be manufactured in the home.3 This perhaps facilitated the initial proliferation of methamphetamine use in the United States in the 1990s and early 2000s.4 In 2005, the Combat Methamphetamine Epidemic Act effectively banned over-the-counter sales of products that contained key ingredients to manufacture methamphetamine such as pseudoephedrine.5 Since then, production of methamphetamine has declined within the United States, and today, a majority of methamphetamine found in the United States being imported in an increasingly inexpensive and potent form.4,6

Rates of substance use, and particularly methamphetamine use, are higher among sexual and gender minority populations (SGM) compared with heterosexuals, and particularly among gay and bisexual and other men who have sex with men (GBM).7 Although recent large scale epidemiological data on methamphetamine use and abuse among GBM is scant, the previous literature has suggested that use of methamphetamine and other amphetamine-type stimulants in GBM is 5–10 times higher than in the general population.8 After significant public health and community attention, methamphetamine use among GBM seemed to decline overall after a peak in 2005.9 However, disaggregated data from Pantalone et al10 indicated that use among HIV-positive GBM again rose to a similar level in 2007 (12.3%) as was observed in 2002 (12.1%), suggesting continued use among vulnerable subpopulations. In addition, more recent studies have found that methamphetamine use in recent years has either remained stable or increased in GBM.11–13

Research dating back to the 1990s and early 2000s has shown an alarming connection between methamphetamine use and risk for HIV infection. As a stimulant, methamphetamine increases sexual libido while simultaneously decreasing behavioral inhibitions.1,2,14 That is, methamphetamine users often report using for sexual enhancement and are simultaneously less likely to use condoms while high.15–17 Methamphetamine additionally reduces the need for sleep, such that users may often go on sexual binges lasting hours, if not days, that involve multiple sexual partners, and often sex without condoms.18 In the United Kingdom and Europe, this has been called “chemsex;” however, chemsex broadly described, can include other drugs such as mephedrone, ecstasy, speed, and gamma hydroxybutyrate, with or without methamphetamine.19–21

With increasing public attention to the ongoing opioid crisis, there seems to be a parallel decrease in attention to the problems methamphetamine poses in GBM communities. A 2020 New York Times article labeled methamphetamine use among sexual minorities “a crisis we are not talking about,” citing an increase in use within the community coupled with paltry funding and support from the public health sector.22 To that end, this study examines methamphetamine use and HIV seroconversion between baseline and month 12 in an ongoing US national cohort study comprised predominately of cisgender GBM but also includes transgender men and transgender women who have sex with men. We specifically examine the association between persistent methamphetamine use between baseline and 12 months with HIV seroconversion relative to nonusers, those who discontinued methamphetamine use after baseline, and those who initiated methamphetamine use after baseline. Our goal is to inform HIV prevention strategies to help end the epidemic in high priority population.



Data are taken from Together 5000 (herein T5K), a US national, internet-based cohort study of men, trans men, and trans women who have sex with men. The goal of T5K is to identify modifiable individual and structural factors associated with HIV seroconversion. Enrollment began in October 2017 using ads on men-for-men geosocial networking phone applications (apps) and concluded in June 2018. The cohort and study procedures have been fully described elsewhere.23–25 In brief, core eligibility criteria for enrollment specified that participants were aged 16–49, had at least 2 male sex partners in the past 3 months, were not currently participating in an HIV vaccine or pre-exposure prophylaxis (PrEP) clinical trial, were not currently on PrEP; lived in the United States or its territories, were not known to be HIV-positive, had a gender identity other than cisgender female, and reported behavioral risk for HIV.

Participants clicking on one of our study ads were routed from geosocial applications to a secured informed consent and enrollment survey webpage that presented questions about demographic characteristics, sexual behavior, and substance use. Of those who completed the enrollment survey, 8755 participants met eligibility criteria and provided contact information for later follow-up. These participants were sent a link to complete a supplemental secondary survey. Of the 8755 eligible, 6267 (71.6%) completed the secondary survey and received a $15 incentive.23,25

After completion of the secondary survey and for an additional $15 incentive, participants were mailed an OraSure HIV-1 specimen collection device26 to use at home. Participants were also provided access to an instructional video along with printed instructions on completing the test. Collection procedures involved taking an oral swab and placing it in an oral fluid container and mailing the specimen using provided prepaid shipping materials to the Wadsworth Center Laboratory of the New York State Department of Health for antibody testing (Avioq HIV-1 Microelisa System, Research Triangle Park, NC). We successfully delivered 6150 HIV test kits to participants, 5065 of which were returned by the laboratory at baseline. At enrollment, 201 participants had HIV-positive results (herein “HIV prevalence”). HIV-positive results were delivered to participants by phone along with referrals to local clinics or other health care providers to link them to care after our clinical protocols.

Month 12 Follow-Up

Twelve months after enrollment, participants were invited through email and text message to complete another online survey as well as at-home HIV testing. Participants who tested HIV positive at baseline (ie, prevalent cases) were not asked to test again. Furthermore, participants who told us on their month 12 survey that they were on PrEP (ie, began PrEP) or that they had been diagnosed with HIV in the year that passed since baseline (ie, diagnosed outside of the study) were not asked to complete testing with us at 12 month follow-up. Instead, participants on PrEP were asked to submit a digital photograph of their prescription bottle showing their name and date. Meanwhile, participants indicating they had been diagnosed with HIV between study assessments were asked to provide proof of status (ie, photo of documentation indicating HIV diagnosis). At 12 months, participants were compensated $25 for completing the online survey and $25 for completing HIV testing (or providing photograph proof of PrEP or HIV-positive diagnosis). For the present analyses, only those participants for whom we had data at baseline and 12-month follow-up were included (n = 4786).


The primary measures of interest were HIV prevalence (at enrollment) and HIV incidence (either diagnosed with HIV at 12 months by our test or reporting that they had been diagnosed with HIV outside of the study between their baseline and 12 month assessments).

Our primary independent variable of interest was self-reported methamphetamine use. At enrollment, participants were asked if they used methamphetamine in the 3 months before baseline (coded yes/no). At month 12, participants were asked to report if they used methamphetamine in the previous year (coded yes/no). Based on these data, participants were categorized into 4 mutually exclusive groups:

  • Abstinent (n = 4127): no methamphetamine use reported in the 3 months before baseline or in the 12 months of prospective follow-up.
  • Baseline only (n = 143): reported methamphetamine use in the 3 months before baseline but no use reported in the 12 months of prospective follow-up.
  • Incident use (n = 94): no methamphetamine use reported in the 3 months before baseline; however, indicated use between baseline and 12-month follow-up.
  • Persistent use (n = 422): reported methamphetamine use in the 3 months before baseline and in the 12 months of prospective follow-up.

Additional covariates of interest included demographic characteristics (eg, age at enrollment, gender identity, race, or ethnicity), history of syphilis infection, and experiences with incarceration (both at enrollment and during follow-up). Both syphilis infection and incarceration are known factors to exacerbate risk of incident HIV infection.

Analysis Plan

We used descriptive statistics—frequencies and percentages—to describe the patterns of prevalence and incidence of methamphetamine use among our geographically diverse study participants from baseline to year 1 follow-up by US census-defined region and state. We also used descriptive statistics to describe prevalence and incidence of methamphetamine use by various sociodemographic characteristics and sexual health factors. To assess differences of methamphetamine use among factor subgroups, we used χ2 tests. Based on findings from these bivariate analyses (P < 0.05) and known factors associated with both HIV and meth use from the literature, we conducted a multivariable logistic regression analysis to determine the magnitude of the association of methamphetamine use with HIV seroconversion at 12-month follow-up. We report adjusted odds ratios (AORs) and 95% confidence intervals (CIs) from this model. All analyses were completed in SAS 9.4.


In Table 1, we report frequencies of methamphetamine use by US census-designated region and state-by-state. At the regional level, there were significant differences in the prevalence and incidence of methamphetamine use. The northeast (5.4%) had the lowest rates of persistent methamphetamine use, compared with the west (11.5%), southeast (9.4%), and midwest (6.7%), χ2 = 35.4, P < 0.001.

TABLE 1. - Regional and State-by-State Prevalence of Methamphetamine Use Between Baseline and 12 Month Follow-Up, Together 5000 Cohort Study, n = 4786, 2017–2019
Total Participants Abstinent: No Use at BL or 12M Baseline Only: BL Use Only, No Use Between BL and 12M Incident Use: Indicated Use Between BL and 12M Persistent Use: Baseline and 12M Use
n = 4786, 100% n = 4127, 86.2% n = 143, 3.0% n = 94, 2.0% n = 422, 8.8%
Frequency % Frequency % Frequency % Frequency % Frequency %
Northeast 738 15.4 660 89.4 24 3.3 14 1.9 40 5.4
 Connecticut 28 0.6 24 85.7 2 7.1 0 0.0 2 7.1
 Maine 5 0.1 5 100.0 0 0.0 0 0.0 0 0.0
 Massachusetts 79 1.7 69 87.3 6 7.6 2 2.5 2 2.5
 New Hampshire 9 0.2 7 77.8 0 0.0 1 11.1 1 11.1
 New Jersey 72 1.5 64 88.9 1 1.4 2 2.8 5 6.9
 New York 394 8.2 359 91.1 11 2.8 7 1.8 17 4.3
 Pennsylvania 131 2.7 113 86.3 3 2.3 2 1.5 13 9.9
 Rhode Island 18 0.4 17 94.4 1 5.6 0 0.0 0 0.0
 Vermont 2 0.0 2 100.0 0 0.0 0 0.0 0 0.0
Southeast 2214 46.3 1894 85.5 62 2.8 50 2.3 208 9.4
 Alabama 74 1.5 61 82.4 3 4.1 2 2.7 8 10.8
 Arkansas 20 0.4 17 85.0 1 5.0 0 0.0 2 10.0
 Delaware 5 0.1 5 100.0 0 0.0 0 0.0 0 0.0
 District of Columbia 37 0.8 32 86.5 0 0.0 0 0.0 5 13.5
 Florida 503 10.5 424 84.3 8 1.6 18 3.6 53 10.5
 Georgia 256 5.4 214 83.6 13 5.1 6 2.3 23 9.0
 Kentucky 42 0.9 37 88.1 0 0.0 0 0.0 5 11.9
 Louisiana 77 1.6 60 77.9 4 5.2 3 3.9 10 13.0
 Maryland 58 1.2 54 93.1 1 1.7 2 3.5 1 1.7
 Mississippi 28 0.6 23 82.1 1 3.6 1 3.6 3 10.7
 North Carolina 182 3.8 158 86.8 4 2.2 3 1.7 17 9.3
 Oklahoma 52 1.1 46 88.5 4 7.7 0 0.0 2 3.9
 South Carolina 59 1.2 56 94.9 0 0.0 0 0.0 3 5.1
 Tennessee 62 1.3 53 85.5 3 4.8 1 1.6 5 8.1
 Texas 647 13.5 554 85.6 19 2.9 12 1.9 62 9.6
 Virginia 92 1.9 83 90.2 1 1.1 2 2.2 6 6.5
 West Virginia 20 0.4 17 85.0 0 0.0 0 0.0 3 15.0
Midwest 729 15.3 650 89.2 15 2.1 15 2.1 49 6.7
 Illinois 185 3.9 173 93.5 3 1.6 3 1.6 6 3.2
 Indiana 76 1.6 60 79.0 3 4.0 4 5.3 9 11.8
 Iowa 29 0.6 26 89.7 1 3.5 2 6.9 0 0.0
 Kansas 29 0.6 26 89.7 1 3.5 1 3.5 1 3.5
 Michigan 67 1.4 62 92.5 1 1.5 2 3.0 2 3.0
 Minnesota 60 1.3 52 86.7 3 5.0 0 0.0 5 8.3
 Missouri 75 1.6 66 88.0 1 1.3 1 1.3 7 9.3
 Nebraska 18 0.4 16 88.9 0 0.0 0 0.0 2 11.1
 North Dakota 6 0.1 4 66.7 0 0.0 1 16.7 1 16.7
 Ohio 117 2.4 104 88.9 1 0.9 0 0.0 12 10.3
 South Dakota 6 0.1 5 83.3 0 0.0 0 0.0 1 16.7
 Wisconsin 61 1.3 56 91.8 1 1.6 1 1.6 3 4.9
West 1084 22.7 904 83.4 42 3.9 13 1.2 125 11.5
 Alaska 10 0.2 9 90.0 0 0.0 0 0.0 1 10.0
 Arizona 89 1.9 70 78.7 4 4.5 3 3.4 12 13.5
 California 550 11.5 450 81.8 23 4.2 6 1.1 71 12.9
 Colorado 99 2.1 85 85.9 5 5.1 1 1.0 8 8.1
 Hawaii 12 0.3 6 50.0 1 8.3 2 16.7 3 25.0
 Idaho 20 0.4 17 85.0 1 5.0 0 0.0 2 10.0
 Montana 14 0.3 11 78.6 0 0.0 0 0.0 3 21.4
 Nevada 52 1.1 41 78.9 4 7.7 1 1.9 6 11.5
 New Mexico 22 0.5 22 100.0 0 0.0 0 0.0 0 0.0
 Oregon 64 1.3 60 93.8 2 3.1 0 0.0 2 3.1
 Utah 48 1.0 35 72.9 2 4.2 0 0.0 11 22.9
 Washington 100 2.1 96 96.0 0 0.0 0 0.0 4 4.0
 Wyoming 4 0.1 2 50.0 0 0.0 0 0.0 2 50.0
 Puerto Rico 19 0.4 17 89.5 0 0.0 2 10.5 0 0.0
 APO or FPO or DPO 2 0.0 2 100.0 0 0.0 0 0.0 0 0.0
12M: 12 months (reported at month 12 with a 12 month recall window); BL, baseline (reported at BL with a 3 month recall window).

In Table 2, we report bivariate associations with patterns of methamphetamine use. All variables were significant. Methamphetamine use was highest among those aged 36–45, specifically for persistent users (15.8% were persistent users). Cisgender men (8.9%) were significantly more likely to be persistent users than gender minority individuals (ie, transgender men, transgender women, and nonbinary, 4.3%). White and Latinx participants were the most likely to report using methamphetamine at some point during the study period; Asians were the least likely. Persistent methamphetamine use was also strongly associated with self-reported reccurring syphilis infections and incarceration (Table 2). Furthermore, methamphetamine use was associated with HIV infection (both at enrollment as well as in the year following enrollment). A total of 251 HIV infections were identified in this study (baseline +12 months), of which 136 were identified at enrollment (2.84% prevalence, 136/4786) and 115 were identified at month 12 (ie, 2.47% annual seroconversions: 4786 enrolled − 136 prevalence = 4650. 115/4650 = 2.47%). Of the 115 participants who seroconverted between baseline and 12 months, 35.7% (greater than one-in-three) were persistent methamphetamine users.

TABLE 2. - Characteristics Associated With Methamphetamine Use at Baseline and/or 12 Month Follow-Up, Together 5000 Cohort Study, n = 4786, 2017–2019
Abstinent: No Use at BL or 12M Baseline Only: BL Use Only, No Use Between BL and 12M Incident Use: Indicated Use Between BL and 12M Persistent Use: Baseline and 12M Use χ2 P
n = 4127, 86.2% n = 143, 3.0% n = 94, 2.0% n = 422, 8.8%
Frequency % Frequency % Frequency % Frequency %
Age at enrolment 134.90 <0.0001
 16–24 yrs old 1010 92.2 26 2.4 30 2.7 30 2.7
 25–35 yrs old 2081 85.7 91 3.8 45 1.9 212 8.7
 36–45 yrs old 797 80.3 20 2.0 18 1.8 157 15.8
 46–55 yrs old 239 88.9 6 2.2 1 0.4 23 8.6
Gender 10.37 0.02
 Male 4029 86.3 135 2.9 89 1.9 417 8.9
 Gender minority 98 84.5 8 6.9 5 4.3 5 4.3
Race/ethnicity 44.72 <0.0001
 White 2202 85.8 64 2.5 43 1.7 259 10.1
 Black 438 90.7 14 2.9 12 2.5 19 3.9
 Latinx 965 85.0 48 4.2 27 2.4 96 8.5
 Asian/Pacific Islander 171 93.4 3 1.6 3 1.6 6 3.3
 All others, multiracial 351 84.4 14 3.4 9 2.2 42 10.1
Incident HIV at 12 mo (HIV diagnoses between BL and 12M) 75.74 <0.0001
 No 4064 87.0 138 3.0 88 1.9 381 8.2
 Yes 63 54.8 5 4.4 6 5.2 41 35.7
Prevalent HIV (baseline and 12 mo) 183.40 <0.0001
 No 3876 88.4 116 2.6 87 2.0 308 7.0
 Yes 138 55.0 18 7.2 6 2.4 89 35.5
 Indeterminate 38 79.2 3 6.3 0 0.0 7 14.6
Syphilis 122.06 <0.0001
 No diagnoses (lifetime) 3786 88.1 116 2.7 84 2.0 314 7.3
 In the year before enrolment 120 76.9 8 5.1 1 0.6 27 17.3
 Incident: diagnosis between enrolment and 12 mo 185 69.6 16 6.0 8 3.0 57 21.4
 Persistent: in the year before enrolment and after enrolment 36 56.3 3 4.7 1 1.6 24 37.5
Incarceration 376.85 <0.0001
 No incarceration in lifetime or during 12 mo follow-up 3682 90.1 93 2.3 84 2.1 227 5.6
 Lifetime: before enrolment but not during 12 mo follow-up 365 66.7 36 6.6 7 1.3 139 25.4
 Incident: incarcerated between enrolment and 12 mo 56 76.7 4 5.5 0 0.0 13 17.8
 Persistent: in the year before enrolment and after enrolment 24 30.0 10 12.5 3 3.8 43 53.8
12M, 12 months (reported at month 12 with a 12 month recall window); BL, baseline (reported at BL with a 3 month recall window).

Next, we performed a multivariable logistic regression to examine factors associated with incident HIV diagnoses between enrollment and month 12 follow-up. For these analyses, prevalent HIV cases at enrollment were excluded. Nearly all of those having seroconverted were GBM; however, 1 was a transgender man, 1 was a transgender woman, and 3 individuals indicated they were gender nonbinary (assigned male sex at birth). Compared with those who did not use methamphetamine, incident methamphetamine users (ie, those who indicated use between baseline and follow-up) and persistent methamphetamine users had significantly higher odds of HIV seroconverting (AOR = 3.95, 95% CI: 1.64 to 9.47; and 7.11, 4.53 to 11.17, respectively). All persistent methamphetamine users who seroconverted were GBM.

Meanwhile, those who reported methamphetamine use before baseline only (ie, had discontinued use between baseline and follow up) did not significantly differ from nonusers in their odds of HIV seroconverting at 12 months. Compared with White participants, Black participants had significantly higher odds of seroconverting (AOR = 2.88, 95% CI: 1.68 to 4.93). Those who reported a syphilis diagnosis between baseline and month 12 were also significantly more likely to have seroconverted (AOR = 2.47, 95% CI: 1.48 to 4.11). Neither age nor incarceration experience between baseline and month 12 were associated with HIV seroconversion (Table 3).

TABLE 3. - Multivariate Logistic Regression, Factors Associated With Incident HIV Diagnoses Between Enrolment and 12 Month Follow-Up, n = 4649*
Estimate aOR 95% CI Pr > χ2
Methamphetamine use
 Never users Ref
 Baseline only use 0.81 2.26 0.88 to 5.78 0.090
 Indicated use between BL and 12M 1.37 3.95 1.64 to 9.47 0.002
 Persistent methamphetamine use at BL and 12M 1.96 7.11 4.53 to 11.17 <0.0001
 16–24 yr old Ref
 25–35 yr old 0.12 1.13 0.67 to 1.91 0.64
 36–45 yr old 0.17 1.19 0.65 to 2.19 0.58
 46–55 yr old −0.19 0.83 0.28 to 2.49 0.74
 White Ref
 Black 1.06 2.88 1.68 to 4.93 0.0001
 Latino 0.02 1.02 0.61 to 1.69 0.94
 Asian/Pacific Islander 0.31 1.37 0.48 to 3.91 0.56
 Others or multiracial 0.42 1.52 0.80 to 2.87 0.20
Syphilis in the past year
 Yes 0.90 2.47 1.48 to 4.11 0.001
 No Ref
Incarcerated in the past year
 Yes 0.36 1.43 0.70 to 2.95 0.33
 No Ref
*To estimate HIV incidence at 12 months, prevalent HIV cases (n = 137) identified at baseline were excluded.
12M, 12 months (reported at month 12 with a 12 month recall window); BL, baseline (reported at BL with a 3 month recall window).


In this study, we examined factors associated with HIV prevalence (at enrollment) and in incident HIV infection in the 12 months after enrollment. An alarming 2.47 per 100 persons of our participants seroconverted between baseline and month 12, which was decidedly higher than observed seroconversions among all GBM in the US nationwide.27 Using 2015 surveillance data, Singh et al estimated an annual US HIV incidence of 513.7/100,000 persons (0.51 per 100 persons) because of male-to-male sexual contact.27 More recent, non–population-based samples of similarly high risk (to T5K participants) SGM have reported incidence estimates of 2.4–2.9.28,29

In total, 13.8% of participants (more than 1 out of every 8) had used methamphetamine at some point in our study's assessment periods—ie, in the 3 months before baseline or in the year after baseline. Furthermore, of those using methamphetamine at baseline (n = 565), 74.7% (422 of 565) were classified as persistent users. In our adjusted logistic regression model, and compared with other variables in the model, being a persistent methamphetamine user was associated with the single greatest odds (AOR = 7.11) of seroconverting.

Methamphetamine exacerbates HIV risk by increasing sexual libido while simultaneously reducing inhibitions.1,2,14 Our findings highlight the need to address methamphetamine use and its associated risks among SGM,30 the likes of which may also serve to help end the HIV epidemic. PrEP in-and-of itself can greatly reduce the risk of HIV infection in the event of exposure, and one study found an association between PrEP use and methamphetamine,1 meaning methamphetamine users were taking advantage of the biological protection PrEP provides. However, we lack sufficient data on the role that methamphetamine plays across the full PrEP care continuum. That is, gaining access to a PrEP provider, renewing a prescription for PrEP, consistently adhering to a dosing schedule, and attending PrEP follow-up visits for long-term care.

Other factors known to be associated with HIV seroconversion risk also evinced themselves in our sample including race and incident syphilis diagnosis. Syphilis diagnosis is a coindicator that sexual behavior without condoms likely occurred and directly serves as a transmission pathway for HIV.31,32 Syphilis rates in the United States have been steadily increasing for 2 decades,33 and our findings highlight the importance of screening for and treating syphilis as well as offering HIV testing combined with sexually transmitted infection testing.

Taken together, findings underscore the urgent need for implementation science research to test novel approaches for delivering scalable, evidence-based substance use interventions to optimize HIV prevention efforts in methamphetamine users. Intensive behavioral interventions such as cognitive-behavioral therapy and contingency management have demonstrated moderate effectiveness for reducing substance use (including methamphetamine) and sexual risk,34,35 including among GBM.36,37 Although mirtazapine has shown some promise as a pharmacologic treatment for methamphetamine use disorder in 2 efficacy trials with SGM who have sex with men (SGMSM),38,39 medication adherence remains a key challenge and the durability of treatment gains remains unclear. Expanded efforts are needed as part of the Ending the HIV Epidemic Initiative30 to develop and test scalable approaches for targeting methamphetamine use as an enduring driver of the HIV epidemic among SGMSM. In particular, novel intervention approaches are needed to optimize engagement along the PrEP care continuum in SGMSM who use methamphetamine.

For clinical providers and community-based groups working with SGMSM—be it for HIV testing, primary health care, social service delivery, etc—our findings suggest an urgent need to include assessments of methamphetamine use among their patients/clients given the alarming strong connection observed with HIV incidence. This is particularly important considering already documented barriers among racial/ethnic minority groups who have limited access to health care, are an increased risk for HIV due to structural racism, and, based on this research findings, are at increased risk of seroconversion due to methamphetamine use. Likewise, those delivering treatment and care targeted to reduce substance use, particularly methamphetamine, would be well served were they to include HIV prevention as part of that service delivery.

Our findings should be understood in light of their limitations. Although the use of at-home HIV testing and photograph verification of HIV status is a strength in our design, not all participants completed these procedures in the study, and our analyses are limited to only those who completed HIV testing or photograph verification of HIV status at baseline and follow-up. It may be that those using methamphetamine may be more difficult to retain, and, thus, we might have underestimated rates of use in this study. Next, online studies have the ability to reach a large number of participants, often at a lower cost than traditional face-to-face studies, but this too can present challenges in longitudinal retention.40 That is, the lack of a face-to-face “human connection” could pose challenges to retention. To enhance participation, we used the OraSure HIV specimen collection device, which is an oral swab, as opposed to a finger-stick blood draw. This is a third generation HIV test with a window period of up to 3 months.26 It is possible that acutely infected participants were not detected at the month 12 assessment, and, thus, our estimates of HIV incidence could be higher than we have reported. However, it is also possible that acutely infected individuals at baseline were not detected at enrollment but were detected at month 12 (ie, were recorded as incident infections). Next, other measures in this study, including methamphetamine use, were self-reported, which could be subject to social desirability biases; however, that effect could be minimized by the use of an online survey, versus a face-to-face assessment methods.40 We also recognize that our measurement methamphetamine use was dichotomous over a long recall period. We recognize that patterns of methamphetamine use can change seasonally over time within individuals and that granularity was not captured in our study.

Web-based recruitment also increases our vulnerability to repeat participation and fraudulent manipulation of HIV testing procedures (eg, someone else's saliva, other than that of the enrolled participant, could be submitted to the laboratory). However, we followed established and effective measures to minimize these risks.40–42 This included advertising only to participants geolocated in the United States, links that expired after one click, blocking multiple submissions from a given IP address, and requiring unique and valid mailing addresses for test kits to be mailed. Furthermore, the incentive for participating in HIV testing as well as participating in the study longitudinally was the same regardless of one's HIV test result. That is, we did not tell participants that they would be disqualified from further participation if their results were HIV positive. Finally, the incentive used at enrollment was fairly low, which can help to disincentivize repeat participation, were someone to figure out how to. Participants were paid $15 for completing the secondary survey and $15 for returning an HIV test kit to the laboratory.

Next, we found an alarming connection between methamphetamine use and HIV prevalence (at enrollment) and incidence (1 year later). Although we believe there is a causal pathway between the 2, we cannot say so for sure. We also lack data on the route in which methamphetamine was used [eg, snorting, smoking, rectal administration (booty bump), or injection]. We can say, however, that nearly all injection drug users also reported methamphetamine use (161 of 171 at enrollment and 231 of 274 at month 12). Both injection drug use (if sharing needles) and rectal administration (booty bumps) can serve to create a direct route for HIV to pass between partners (the risk posed by needle sharing is perhaps self-evident, whereas booty bumps compound risk through the damage that methamphetamine itself can do to the lining of the rectum, and booty bumps are often followed by anal sex).


An alarming number of individuals HIV seroconverted within a year of joining this study and HIV prevalence (at enrollment) as well as HIV seroconversion was strongly associated with methamphetamine use. In addition, HIV seroconversion was particularly high among those having persisted in their use from before baseline into the 12 months of follow-up. Urgent measures are needed to curb methamphetamine use and its associated risk factors. Providers conducting HIV testing to GBM should simultaneously assess for methamphetamine use. If their patients report use, appropriate referrals for harm reduction both in sexual behavior and drug use, should be given to patients. PrEP can greatly reduce the biological risks of HIV infection; however, more data are needed to understand how methamphetamine may serve as a barrier to PrEP initiation, adherence, and long-term retention in care.


Special thanks to additional members of the T5K study team: David Pantalone, Sarit A. Golub, Viraj V. Patel, Gregorio Millett, Don Hoover, Sarah Kulkarni, Matthew Stief, Chloe Mirzayi, Javier Lopez-Rios, Alexa D'Angelo, and Pedro B. Carneiro. Thank you to the program staff at NIH: Gerald Sharp, Sonia Lee, and Michael Stirratt. Thank you to the members of our scientific advisory board: Michael Camacho, Demetre Daskalakis, Sabina Hirshfield, Jeremiah Johnson, Claude Mellins, and Milo Santos. Although the NIH financially supported this research, the content is the responsibility of the authors and does not necessarily reflect official views of the NIH.


1. Hammoud MA, Jin F, Maher L, et al. Biomedical HIV protection among gay and bisexual men who use crystal methamphetamine. AIDS Behav. 2020;24:1400–1413.
2. Bryant J, Hopwood M, Dowsett GW, et al. The rush to risk when interrogating the relationship between methamphetamine use and sexual practice among gay and bisexual men. Int J Drug Pol. 2018;55:242–248.
3. Hearne E, Alves EA, Van Hout MC, et al. Home manufacture of drugs: an online investigation and a toxicological reality check of online discussions on drug chemistry. J Psychoactive Drugs. 2017;49:279–288.
4. Goodnough A. A new drug scourge: deaths involving meth are rising fast. The New York Times. December 17, 2019. Available at: Accessed March 9, 2020.
5. US Department of Justice Drug Enforcement Administration. The combat methamphetamine epidemic act of 2005. 2005. Available at: Accessed March 9, 2020.
6. US Department of Justice Drug Enforcement Administration. National drug threat assessment summary. 2015. Available at: Accessed March 9, 2020.
7. Mansergh G, Purcell DW, Stall R, et al. CDC consultation on methamphetamine use and sexual risk behavior for HIV/STD infection: summary and suggestions. Public Health Rep. 2006;121:127–132.
8. Shoptaw S. Methamphetamine use in urban gay and bisexual populations. Top HIV Med. 2006;14:84–87.
9. Reback CJ, Shoptaw S, Grella CE. Methamphetamine use trends among street-recruited gay and bisexual males, from 1999 to 2007. J Urban Health. 2008;85:874–879.
10. Pantalone DW, Bimbi DS, Holder CA, et al. Consistency and change in club drug use by sexual minority men in New York City, 2002 to 2007. Am J Public Health. 2010;100:1892–1895.
11. Hoots BE, Broz D, Nerlander L, et al. Changes in prescription opioid, meth, and cocaine use among MSM in 20 US cities. Paper presented at: Conference on Retovirus and Opportunistic Infections (CROI); February 16, 2017; Seattle, WA.
12. Centers for Disease Control and Prevention. HIV infection risk, prevention, and testing behaviors among men who have sex with men—National HIV Behavioral Surveillance, 23 U.S. cities. HIV surveillance special report 2019. 2017. Available at: Accessed March 9, 2020.
13. Thu Vu NT, Maher L, Zablotska I. Amphetamine‐type stimulants and HIV infection among men who have sex with men: implications on HIV research and prevention from a systematic review and meta‐analysis. J Int AIDS Soc. 2015;18:19273.
14. Knight R, Karamouzian M, Carson A, et al. Interventions to address substance use and sexual risk among gay, bisexual and other men who have sex with men who use methamphetamine: a systematic review. Drug Alcohol Depend. 2019;194:410–429.
15. Halkitis PN, Parsons JT, Stirratt MJ. A double epidemic: crystal methamphetamine drug use in relation to HIV transmission. J Homosex. 2001;41:17–35.
16. Isaiah Green A, Halkitis PN. Crystal methamphetamine and sexual sociality in an urban gay subculture: an elective affinity. Cult Health Sex. 2006;8:317–333.
17. Baskin-Sommers A, Sommers I. The co-occurrence of substance use and high-risk behaviors. J Adolesc Health. 2006;38:609–611.
18. Semple SJ, Zians J, Strathdee SA, et al. Sexual marathons and methamphetamine use among HIV-positive men who have sex with men. Arch Sex Behav. 2009;38:583.
19. McCall H, Adams N, Mason D, et al. What is chemsex and why does it matter? BMJ. 2015;351:h5790.
20. Giorgetti R, Tagliabracci A, Schifano F, et al. When “chems” meet sex: a rising phenomenon called “chemsex”. Curr Neuropharmacology. 2017;15:762–770.
21. Sewell J, Miltz A, Lampe FC, et al. Poly drug use, chemsex drug use, and associations with sexual risk behaviour in HIV-negative men who have sex with men attending sexual health clinics. Int J Drug Pol. 2017;43:33–43.
22. Mangia J. Gay men are dying from a crisis we're not talking about. The New York Times. March 9, 2020. Available at: Accessed March 9, 2020.
23. Grov C, Westmoreland DA, Carneiro PB, et al. Recruiting vulnerable populations to participate in HIV prevention research: findings from the together 5000 cohort study. Ann Epidemiol. 2019;35:4–11.
24. Nash D, Stief M, MacCrate C, et al. A web-based study of HIV prevention in the era of pre-exposure prophylaxis among vulnerable HIV-negative gay and bisexual men, transmen, and transwomen who have sex with men: protocol for an observational cohort study. JMIR Res Protoc. 2019;8:e13715.
25. Grov C, Stief M, Westmoreland DA, et al. Maximizing response rates to ads for free at-home HIV testing on a men-for-men geosocial sexual networking app: lessons learned and implications for researchers and providers. Health Educ Behav. 2020;47:5–13.
26. OraSure Technologies. OraSure HIV-1 oral specimen collection device. 2013. Available at: Accessed July 8, 2020.
27. Singh S, Song R, Johnson AS, et al. HIV incidence, prevalence, and undiagnosed infections in US men who have sex with men. Ann Intern Med. 2018;168:685–694.
28. Pathela P, Jamison K, Braunstein SL, et al. Incidence and predictors of HIV infection among men who have sex with men attending public sexually transmitted disease clinics, New York City, 2007–2012. AIDS Behav. 2017;21:1444–1451.
29. Mustanski B, Ryan DT, Newcomb ME, et al. Very high HIV incidence and associated risk factors in a longitudinal cohort study of diverse adolescent and young adult men who have sex with men and transgender women. AIDS Behav. 2020;24:1966–1975.
30. Ending the HIV epidemic: a plan for America. 2020. Available at: Accessed July 8, 2020.
31. Sullivan PS, Purcell DW, Grey JA, et al. Patterns of racial/ethnic disparities and prevalence in HIV and syphilis diagnoses among men who have sex with men, 2016: a novel data visualization. Am J Public Health. 2018;108:S266–S273.
32. Girometti N, Gutierrez A, Nwokolo N, et al. High HIV incidence in men who have sex with men following an early syphilis diagnosis: is there room for pre-exposure prophylaxis as a prevention strategy? Sex Transm Infect. 2017;93:320–322.
33. de Voux A, Kidd S, Grey JA, et al. State-specific rates of primary and secondary syphilis among men who have sex with men—United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66:349–354.
34. Shoptaw S, Montgomery B, Williams CT, et al. Not just the needle: the state of HIV prevention science among substance users and future directions. J Acquir Immune Defic Syndr. 2013;63:S174–S178.
35. Colfax G, Santos G-M, Chu P, et al. Amphetamine-group substances and HIV. The Lancet. 2010;376:458–474.
36. Carrico AW, Zepf R, Meanley S, et al. When the party is over: a systematic review of behavioral interventions for substance-using men who have sex with men. J Acquir Immune Defic Syndr. 2016;73:299.
37. Carrico AW, Flentje A, Gruber VA, et al. Community-based harm reduction substance abuse treatment with methamphetamine-using men who have sex with men. J Urban Health. 2014;91:555–567.
38. Coffin PO, Santos G-M, Hern J, et al. Effects of mirtazapine for methamphetamine use disorder among cisgender men and transgender women who have sex with men: a placebo-controlled randomized clinical trial. JAMA Psychiatry. 2019;77:246–255.
39. Colfax GN, Santos G-M, Das M, et al. Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Arch Gen Psychiatry. 2011;68:1168–1175.
40. Grov C, Westmoreland D, Rendina HJ, et al. Seeing is believing? Unique capabilities of internet-only studies as a tool for implementation research on HIV prevention for men who have sex with men: a review of studies and methodological considerations. J Acquir Immune Defic Syndr. 2019;82:S253–S260.
41. Bauermeister JA, Pingel E, Zimmerman M, et al. Data quality in HIV/AIDS web-based surveys: handling invalid and suspicious data. Field Methods. 2012;24:272–291.
42. Khosropour CM, Johnson BA, Ricca AV, et al. Enhancing retention of an Internet-based cohort study of men who have sex with men (MSM) via text messaging: randomized controlled trial. J Med Int Res. 2013;15:e194.

methamphetamine; HIV incidence; HIV prevalence; gay and bisexual men; sexual and gender minorities; syphilis

Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.